<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Virax Biolabs Group Limited — News on 6ix</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares</link>
<description>Latest news and press releases for Virax Biolabs Group Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 26 May 2026 11:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/virax-biolabs-group-limited-ordinary-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d3c078dffbe2df120b17.webp</url>
<title>Virax Biolabs Group Limited</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares</link>
</image>
<item>
<title>Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-reports-positive-early-clinical-data-for-viraximmunetm-in-long-covid-and-related-post-acute-infection-syndromes</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-reports-positive-early-clinical-data-for-viraximmunetm-in-long-covid-and-related-post-acute-infection-syndromes</guid>
<pubDate>Tue, 26 May 2026 11:30:00 GMT</pubDate>
<description>Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value ("PPV") — early pe</description>
</item>
<item>
<title>Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-achieves-iso-certifications-laying-foundation-for-regulated-ivd-development-and-us-clinical-validation</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-achieves-iso-certifications-laying-foundation-for-regulated-ivd-development-and-us-clinical-validation</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>LONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited,</description>
</item>
<item>
<title>Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-group-limited-announces-210500139</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-group-limited-announces-210500139</guid>
<pubDate>Thu, 04 Dec 2025 21:05:00 GMT</pubDate>
<description>Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement of its securities for total gross proceeds of $5 million, before deducting placement agent fees and other offering expenses.</description>
</item>
<item>
<title>Virax Biolabs Group Limited Announces $5 Million Private Placement</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-group-limited-announces-185300741</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-group-limited-announces-185300741</guid>
<pubDate>Wed, 03 Dec 2025 18:53:00 GMT</pubDate>
<description>Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the purchase and sale of 12,500,000 ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares at a purchase price of $0.40 per ordinary share and associated preferred invest</description>
</item>
<item>
<title>Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-ceo-james-foster-123400241</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-ceo-james-foster-123400241</guid>
<pubDate>Wed, 03 Dec 2025 12:34:00 GMT</pubDate>
<description>Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors.</description>
</item>
<item>
<title>Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-completes-uk-clinical-132900389</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-completes-uk-clinical-132900389</guid>
<pubDate>Mon, 03 Nov 2025 13:29:00 GMT</pubDate>
<description>Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases, today announced that it has successfully completed patient recruitment for its United Kingdom-based, multi-centre clinical study evaluating the performance of the ViraxImmune™ assay in detecting T cell dysfunction in Post-Acute Infection Syndromes ("PAIS"), including Long COVID, post-treatment Lyme disease ("PT</description>
</item>
<item>
<title>Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-partners-emory-university-113000866</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-partners-emory-university-113000866</guid>
<pubDate>Tue, 26 Aug 2025 11:30:00 GMT</pubDate>
<description>Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immune response detection and diagnostics, today announced it has signed a Research Services Agreement ("RSA") with Emory University's Center for the Advancement of Diagnostics for a Just Society ("ADJUST Center") to conduct clinical studies of ViraxImmune™. These studies will focus on immune profiling in individuals with post-viral syndromes, beginning with post-acute sequelae o</description>
</item>
<item>
<title>Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-appoints-iain-miller-113500960</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-appoints-iain-miller-113500960</guid>
<pubDate>Tue, 29 Jul 2025 11:35:00 GMT</pubDate>
<description>Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced the appointment of Iain Miller, PhD as an Independent Director to its Board of Directors, effective 29 July 2025.</description>
</item>
<item>
<title>Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-receipt-nasdaq-201500745</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-receipt-nasdaq-201500745</guid>
<pubDate>Fri, 18 Jul 2025 20:15:00 GMT</pubDate>
<description>Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced that it received a notice from The Nasdaq Stock Market LLC ("Nasdaq") dated July 14, 2025, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2)(the "Minimum Bid Price Rule") for continued listing on the NASDAQ.</description>
</item>
<item>
<title>Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-enrolls-first-patients-113000148</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-enrolls-first-patients-113000148</guid>
<pubDate>Tue, 18 Mar 2025 11:30:00 GMT</pubDate>
<description>Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it has started enrolling patients into its United Kingdom based, multi-center clinical study (NCT06731179).</description>
</item>
<item>
<title>Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-presents-data-t-113000013</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-presents-data-t-113000013</guid>
<pubDate>Thu, 13 Mar 2025 11:30:00 GMT</pubDate>
<description>Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in post-acute infection syndromes (PAIS) at the World Immune Regulation Meeting (WIRM) in Davos, Switzerland.</description>
</item>
<item>
<title>Virax Biolabs to Present at 19th World Immune Regulation Meeting</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-present-19th-world-123000194</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-present-19th-world-123000194</guid>
<pubDate>Wed, 05 Mar 2025 12:30:00 GMT</pubDate>
<description>Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced that the company's management will present at the 19th World Immune Regulation Meeting (WIRM), which will take place March 12-15, 2025, in Davos, Switzerland.</description>
</item>
<item>
<title>Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-believes-technology-aligns-120000244</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-believes-technology-aligns-120000244</guid>
<pubDate>Tue, 25 Feb 2025 12:00:00 GMT</pubDate>
<description>Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") believes that its technology aligns with the United States Department of Health and Human Services' commitment to prioritizing transparency on vaccine efficacy. This initiative is essential for empowering the public with the information needed to make informed health decisions.</description>
</item>
<item>
<title>Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-agreement-with-tebubio-to-expand-distribution-of-immuneselect-across-the-european-union-norway-and-switzerland</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-agreement-with-tebubio-to-expand-distribution-of-immuneselect-across-the-european-union-norway-and-switzerland</guid>
<pubDate>Tue, 10 Dec 2024 05:00:00 GMT</pubDate>
<description>LONDON, Dec. 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on</description>
</item>
<item>
<title>Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-distribution-agreement-with-europa-biosite-to-commercialize-immuneselect-in-the-united-kingdom-and-ireland</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-distribution-agreement-with-europa-biosite-to-commercialize-immuneselect-in-the-united-kingdom-and-ireland</guid>
<pubDate>Wed, 23 Oct 2024 04:00:00 GMT</pubDate>
<description>LONDON, Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on</description>
</item>
<item>
<title>Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc.</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-extension-of-existing-exclusive-distribution-agreement-to-market-mpox-formerly-monkeypox-virus-real-time-pcr-detection-kits-with-cosmos-health-inc-1</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-extension-of-existing-exclusive-distribution-agreement-to-market-mpox-formerly-monkeypox-virus-real-time-pcr-detection-kits-with-cosmos-health-inc-1</guid>
<pubDate>Mon, 16 Sep 2024 04:00:00 GMT</pubDate>
<description>LONDON, Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on</description>
</item>
<item>
<title>Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-distribution-agreement-to-commercialize-mpox-formerly-monkeypox-virus-rt-pcr-detection-kits-in-europe-and-the-middle-east</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-announces-distribution-agreement-to-commercialize-mpox-formerly-monkeypox-virus-rt-pcr-detection-kits-in-europe-and-the-middle-east</guid>
<pubDate>Wed, 28 Aug 2024 04:00:00 GMT</pubDate>
<description>LONDON, Aug. 28, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on</description>
</item>
<item>
<title>Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-group-limited-announces-dollar5-million-registered-direct-offering-of-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-group-limited-announces-dollar5-million-registered-direct-offering-of-ordinary-shares</guid>
<pubDate>Wed, 21 Aug 2024 04:00:00 GMT</pubDate>
<description>LONDON, Aug. 21, 2024 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on</description>
</item>
<item>
<title>Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-launches-portfolio-of-immune-profiling-solutions-evaluating-adaptive-immunity-in-post-viral-syndromes-at-escmid-global-2024</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-launches-portfolio-of-immune-profiling-solutions-evaluating-adaptive-immunity-in-post-viral-syndromes-at-escmid-global-2024</guid>
<pubDate>Thu, 25 Apr 2024 04:00:00 GMT</pubDate>
<description>LONDON, April 25, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on</description>
</item>
<item>
<title>Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients</title>
<link>https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-forges-strategic-research-collaboration-with-university-of-manchester-and-the-northern-care-alliance-foundation-trust-to-enhance-understanding-of-immune-responses-in-covid-patients</link>
<guid isPermaLink="true">https://6ix.com/company/virax-biolabs-group-limited-ordinary-shares/news/virax-biolabs-forges-strategic-research-collaboration-with-university-of-manchester-and-the-northern-care-alliance-foundation-trust-to-enhance-understanding-of-immune-responses-in-covid-patients</guid>
<pubDate>Thu, 21 Dec 2023 05:00:00 GMT</pubDate>
<description>LONDON, Dec. 21, 2023 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on</description>
</item>
</channel>
</rss>